Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a condition called multicentric Castleman's disease, which is a rare disorder affecting the lymph nodes. A total of 79 people took part — 53 received a medicine called siltuximab alongside best supportive care (standard care aimed at managing symptoms), and 26 received a placebo (a dummy treatment) alongside best supportive care. The trial's main goal was to measure how many participants had a meaningful and lasting shrinkage of their disease along with an improvement in symptoms, sustained for at least 18 weeks. The reported data shows that, for the main outcome, 34% of participants in the siltuximab group met the criteria for this combined tumour and symptom response, compared with 0% in the placebo group. For the secondary outcomes, the reported data shows that among those in the siltuximab group who did respond, the median time they maintained that response was 383 days (roughly 13 months). Looking at tumour shrinkage alone (without the symptom requirement), 37.7% of the siltuximab group and 3.8% of the placebo group met the criteria, with a median duration of 356 days versus 70 days respectively. The trial also tracked how long it was before treatment was considered to have stopped working — the reported figure for the placebo group was 134 days, while a median figure for the siltuximab group was not reached during the study period. Additionally, 61.3% of participants in the siltuximab group and 0% in the placebo group reached a pre-specified increase in haemoglobin (a measure of red blood cells) by week 13; this figure for the placebo group was not reported separately for the duration outcome. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 35793409) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Castleman Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Multicentric Castleman's Disease that is measurable and causing symptoms
- Your heart, liver, kidneys, and other organs are functioning well enough, based on blood tests reviewed by the study doctor
- You are fairly active and able to carry out daily activities, based on a standard health scale (scored 0, 1, or 2 out of 4)
- If you are taking steroid medication (such as prednisone), your dose is no more than 1 mg per kg of your body weight per day, and the dose has stayed the same or been reduced in the 4 weeks before starting the trial
Who may not be able to join:
- You have tested positive for HIV (Human Immunodeficiency Virus) or HHV-8 (Human Herpes Virus-8)
- Your only measurable sign of Multicentric Castleman's Disease is skin lesions
- You have a previous history of lymphoma (a type of blood cancer)
- You have or have had another type of cancer, unless it was a minor skin cancer that was treated successfully, a very early-stage cervical condition, or another cancer (not lymphoma) that you have been completely free of for 3 or more years
- You have another medical condition or illness that could interfere with taking part in the study (confirm with trial site)
- You have previously been treated with therapies that target a protein called Interleukin-6 or its receptor
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Who Achieved Durable Tumor and Symptomatic Response - by Independent Radiology Review
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.